339 related articles for article (PubMed ID: 31677034)
1. Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion.
Nedaeinia R; Faraji H; Javanmard SH; Ferns GA; Ghayour-Mobarhan M; Goli M; Mashkani B; Nedaeinia M; Haghighi MHH; Ranjbar M
Mol Biol Rep; 2020 Jan; 47(1):819-841. PubMed ID: 31677034
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action and thrombolytic potential of staphylokinase.
Lijnen HR
Verh K Acad Geneeskd Belg; 1995; 57(4):303-14. PubMed ID: 8571666
[TBL] [Abstract][Full Text] [Related]
3. Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis.
Collen D; Lijnen HR; Vanderschueren S
Verh K Acad Geneeskd Belg; 1995; 57(3):183-96; discussion 196-8. PubMed ID: 7483814
[TBL] [Abstract][Full Text] [Related]
4. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.
Collen D; De Cock F; Stassen JM
Circulation; 1993 Mar; 87(3):996-1006. PubMed ID: 8443918
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models.
Nagai N; Vanlinthout I; Collen D
Circulation; 1999 Dec 21-28; 100(25):2541-6. PubMed ID: 10604893
[TBL] [Abstract][Full Text] [Related]
6. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of staphylokinase, streptokinase and tissue-type plasminogen activator on the lysis of retracted human plasma clots and fibrinolytic plasma parameters in vitro.
Hauptmann J; Glusa E
Blood Coagul Fibrinolysis; 1995 Sep; 6(6):579-83. PubMed ID: 7578902
[TBL] [Abstract][Full Text] [Related]
8. Engineering of a staphylokinase-based fibrinolytic agent with antithrombotic activity and targeting capability toward thrombin-rich fibrin and plasma clots.
Lian Q; Szarka SJ; Ng KK; Wong SL
J Biol Chem; 2003 Jul; 278(29):26677-86. PubMed ID: 12736246
[TBL] [Abstract][Full Text] [Related]
9. New developments in thrombolytic therapy.
Collen DC; Gold HK
Thromb Res Suppl; 1990; 10():105-31. PubMed ID: 2180114
[TBL] [Abstract][Full Text] [Related]
10. Reteplase: a review of its use in the management of thrombotic occlusive disorders.
Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
Am J Cardiovasc Drugs; 2006; 6(4):265-85. PubMed ID: 16913828
[TBL] [Abstract][Full Text] [Related]
11. Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.
Aisina RB; Moukhametova LI; Varfolomeyev SD
Biochemistry (Mosc); 2003 Nov; 68(11):1252-60. PubMed ID: 14640969
[TBL] [Abstract][Full Text] [Related]
12. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.
Lijnen HR; Stassen JM; Vanlinthout I; Fukao H; Okada K; Matsuo O; Collen D
Thromb Haemost; 1991 Oct; 66(4):468-73. PubMed ID: 1796398
[TBL] [Abstract][Full Text] [Related]
13. [Staphylokinase--a specific plasminogen activator].
Rozpończyk E; Szemraj J; Malinowski M; Rozpończyk J
Postepy Biochem; 2006; 52(1):80-6. PubMed ID: 16869305
[TBL] [Abstract][Full Text] [Related]
14. Spotlight on reteplase in thrombotic occlusive disorders.
Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
BioDrugs; 2007; 21(1):65-8. PubMed ID: 17263591
[TBL] [Abstract][Full Text] [Related]
15. Novel and emerging therapies: thrombus-targeted fibrinolysis.
Lippi G; Mattiuzzi C; Favaloro EJ
Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
[TBL] [Abstract][Full Text] [Related]
16. Hidden Potential of Highly Efficient and Widely Accessible Thrombolytic Staphylokinase.
Toul M; Mican J; Slonkova V; Nikitin D; Marek M; Bednar D; Damborsky J; Prokop Z
Stroke; 2022 Oct; 53(10):3235-3237. PubMed ID: 36039755
[TBL] [Abstract][Full Text] [Related]
17. Newer thrombolytic drugs for acute myocardial infarction.
Reddy DS
Indian J Exp Biol; 1998 Jan; 36(1):1-15. PubMed ID: 9536645
[TBL] [Abstract][Full Text] [Related]
18. The biotechnological potential of fibrinolytic enzymes in the dissolution of endogenous blood thrombi.
Kotb E
Biotechnol Prog; 2014; 30(3):656-72. PubMed ID: 24799449
[TBL] [Abstract][Full Text] [Related]
19. [Thrombolytic therapy of ischemic stroke].
Gusev EI; Martynov MY; Yasamanova AN; Nikonov AA; Markin SS; Semenov AM
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(12. Vyp. 2):4-14. PubMed ID: 30830111
[TBL] [Abstract][Full Text] [Related]
20. [Staphylokinase for a better thrombolytic treatment of heart and platelet diseases].
Vanderschueren S
Verh K Acad Geneeskd Belg; 2000; 62(1):69-75. PubMed ID: 10769618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
